

Supplementary Table 3. Comparison of outcomes between combination (vigabatrin and hormonal) therapy and vigabatrin monotherapy

Outcome	Combination therapy (N=115)	Vigabatrin monotherapy (N=240)	Odds ratio (95% CI)	P value
Seizure free	34 (29.6)	43 (17.9)	0.52 (0.30–0.91)	0.019
Seizure controlled with ASM	21 (18.3)	71 (29.6)	1.88 (1.06–3.43)	0.027
Nondisabling seizures with ASM	28 (24.3)	50 (20.8)	0.82 (0.47–1.45)	0.494
Drug-resistant epilepsy	32 (27.8)	76 (31.7)	1.20 (0.72–2.04)	0.538
Intellectual disability	95 (82.6)	199 (82.9)	1.30 (0.57–2.85)	0.564

Values are presented as number (%) unless otherwise indicated.

ASM, antiseizure medication; CI, confidence interval.

Odds ratios were calculated using vigabatrin monotherapy as a reference.

Boldface indicates a statistically significant difference with $P < 0.05$.